Peter Pitts was appointed as Director at BRAINSTORM CELL THERAPEUTICS INC..
“appointed Peter Pitts to serve as a director of the Company, effective as of the same day”
BRAINSTORM CELL THERAPEUTICS INC. — fact timeline
Source-grounded facts extracted from BRAINSTORM CELL THERAPEUTICS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BRAINSTORM CELL THERAPEUTICS INC. reported the three months ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was approximately $2.1 million, EPS Net loss per share for the three months ended March 31, 2026 and 2025 was $(0.19) and $(0.45), respectively..
“BrainStorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”
BRAINSTORM CELL THERAPEUTICS INC. reported the full year ended December 31, 2025 results: net income Net loss for the twelve months ended December 31, 2025, was approximately $10.3 million, EPS Net loss per share for the twelve months ended December 31, 2025, and 2024 was $1.11 and $2.31, respectively.
“On March 31, 2026, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”
BRAINSTORM CELL THERAPEUTICS INC. issued 120% of the total number of shares and Pre-Funded Warrants purchased by the Investor of warrant to accredited investor for $1.00 per share exercise price.
“The Company will also issue to the investors common stock purchase warrants (the " Common Warrants ," and together with the shares of Common Stock and Pre-Funded Warrants sold, the " Securities ") exercisable for a number of shares equal to 120% of the total number of shares and Pre-Funded Warrants purchased by the Investor, with an exercise price of $1.00 per share, subject to adjustment.”
BRAINSTORM CELL THERAPEUTICS INC. issued $125,000 at the first closing and an additional $875,000 on up to seven additional closings of common stock to accredited investor for $0.60 per share.
“at the first closing and an additional $875,000 on up to seven additional closings. The final closing must be no later than Septembner 25, 2026. The per share purchase price is $0.60 and the per Pre-Funded Warrant purchase price is $0.60 less $0.0005, and each Pre-Funded Warrant has an exercise price of $0.00005 per share. The Investor may elect to receive”
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with an accredited investor valued at $1,000,000 (effective 2026-02-24).
“On February 24, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an accredited investor (the “ Investor ”), pursuant to which the Company agreed to sell, in a private placement, shares of its common stock, par value $0.00005 per share (the “ Common Stock ”), and, in lieu of shares as elected by an investor, pre-funded warrants to purchase Common Stock (the “ Pre-Funded Warrants ). The transaction will occur in up to eight closings. The aggregate subscription amount under the Purchase Agreement is $1,000,000, consisting of $125,000 at the first closing and an additional $875,000 on up to seven additional closings.”
BRAINSTORM CELL THERAPEUTICS INC. issued a number of shares equal to 120% of the total number of shares and Pre-Funded Warrants purchased by the Investor of warrant to accredited investor.
“exercisable for a number of shares equal to 120% of the total number of shares and Pre-Funded Warrants purchased by the Investor, with an exercise price of $1.00 per share”
BRAINSTORM CELL THERAPEUTICS INC. issued warrant to accredited investor for $0.60 less $0.0005 per Pre-Funded Warrant.
“subscription amount under the Purchase Agreement is $1,000,000, consisting of $500,000 at the first closing and $500,000 at the second closing. The per share purchase price is $0.60 and the per Pre-Funded Warrant purchase price is $0.60 less $0.0005, and each Pre-Funded Warrant has an exercise price of $0.00005 per share. The Investor may elect to receive”
BRAINSTORM CELL THERAPEUTICS INC. issued common stock to accredited investor for $0.60 per share.
“subscription amount under the Purchase Agreement is $1,000,000, consisting of $500,000 at the first closing and $500,000 at the second closing. The per share purchase price is $0.60 and the per Pre-Funded Warrant purchase price is $0.60 less $0.0005, and each Pre-Funded Warrant has an exercise price of $0.00005 per share. The Investor may elect to receive”
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with an accredited investor valued at $1,000,000 (effective 2026-02-09).
“On February 9, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an accredited investor (the “ Investor ”), pursuant to which the Company agreed to sell, in a private placement, shares of its common stock, par value $0.00005 per share (the “ Common Stock ”), and, in lieu of shares as elected by an investor, pre-funded warrants to purchase Common Stock (the “ Pre-Funded Warrants ).”
BRAINSTORM CELL THERAPEUTICS INC. issued shares of common stock issuable upon conversion of the Notes of convertible note to accredited investors for not specified.
“The Notes, and the shares of the Company’s common stock issuable upon conversion of the Notes, if any, were or will be issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D thereunder.”
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with Auctus Fund, LLC valued at aggregate principal amount of $140,000 (effective 2026-01-06).
“On January 6, 2026, the Company entered into a Securities Purchase Agreement with Auctus Fund, LLC, under which the Company issued a convertible promissory note in the aggregate principal amount of $140,000, including a $14,000 original issue discount, for cash proceeds of $126,000”
BRAINSTORM CELL THERAPEUTICS INC. entered into Note Purchase Agreement with Quick Capital, LLC valued at principal amount of $94,875 (effective 2026-01-05).
“On January 5, 2026, the Company entered into a Note Purchase Agreement with Quick Capital, LLC, under which the Company issued a convertible promissory note in the principal amount of $94,875”
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with Vanquish Funding Group Inc. valued at aggregate principal amount of $94,300 (effective 2025-12-31).
“On December 31, 2025, the Company entered into a Securities Purchase Agreement with Vanquish Funding Group Inc., under which the Company issued a note in the aggregate principal amount of $94,300 (including $12,300 original issue discount) for aggregate purchase price proceeds of $82,000”
BRAINSTORM CELL THERAPEUTICS INC. issued convertible note to Labrys Fund II, L.P. for principal amount of $143,750 (including $18,750 of original issue discount) and received funds of $121,500 after legal fees of $3,500.
“On November 10, 2025, Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Labrys Fund II, L.P., a Delaware limited partnership (“ Labrys ”), pursuant to which the Company issued to Labrys a promissory note (the “ Note ”) in the principal amount of $143,750 (including $18,750 of original issue discount) and received funds of $121,500 after legal fees of $3,500.”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“July 16, 2025, Brainstorm Cell Therapeutics Inc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of trading on July 18, 2025. The Company has applied and been approved to have its common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT”
BRAINSTORM CELL THERAPEUTICS INC.: Reduced quorum requirement for stockholder meetings from majority to one-third (effective 2025-04-20).
“On April 20, 2025, the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) approved an amendment (“ Bylaws Amendment”) to the Company’s bylaws, as amended, to reduce the quorum requirement for all meetings of stockholders from a majority in interest of all of the Company’s stock that is issued and outstanding and entitled to vote to one-third (1/3) in interest of all of the Company’s stock that is issued and outstanding and entitled to vote at such meeting, as permitted under the Delaware General Corporation Law.”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq hearing update notice regarding market value.
“January 21, 2025, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On the same day, the Company received a letter from Nasdaq notifying the Company that, among other things, (i) the Panel hearing will be held on February 25, 2025, and (ii) the hearing request submitted by the Company has stayed the delisting action pending a final written decision by the Panel. At the hearing, the Company will demonstrate its ability to regain compliance with the deficiencies cited by the Staff, as well as its ability to sustain long-term c”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq hearing update notice regarding market value.
“January 21, 2025, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On the same day, the Company received a letter from Nasdaq notifying the Company t”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“January 15, 2025, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company requests an appeal of Nasdaq’s determination to delist the Company’s common stock from The Nasdaq Capital Market by January 22, 2025, the Company’s common stock will be delisted from The Nasdaq Capital Market at the opening of business on January 24, 2025. While the Company intends to appeal Nasdaq’s decision, no guarantee can be provided that it will be successful in doing so and t”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“January 15, 2025, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company reque”
Hartoun Hartounian was appointed as Executive Vice President and Chief Operating Officer at BRAINSTORM CELL THERAPEUTICS INC..
“On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 1, 2024, the Company received a staff determination letter (“Staff Letter”) from the Staff of Nasdaq indicating that the Company had not regained compliance with the Minimum Bid Price Requirement by April 29, 2024. Pursuant to the Nasdaq Listing Rules and the Staff Letter, if the Company does not request an appeal of the Staff’s determination by May 8, 2024, the Company’s securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on May 10, 2024, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the”
Stacy Lindborg was appointed as member of the Board at BRAINSTORM CELL THERAPEUTICS INC..
“Dr. Lindborg has been appointed to serve as a member of the Board, with effect from the Separation Date.”
Stacy Lindborg resigned as Co-Chief Executive Officer at BRAINSTORM CELL THERAPEUTICS INC..
“Dr. Stacy Lindborg, the Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. (the “Company”), provided the Company with notice of her intent to resign from her current role at the Company, effective as of May 9, 2024.”
BRAINSTORM CELL THERAPEUTICS INC. amended Distribution Agreement with Leerink Partners LLC (effective 2024-04-02).
“On April 2, 2024, the Company entered into an amendment No. 1 to the Distribution Agreement (“Amendment No. 1”) pursuant to which Leerink Partners ceased to be an agent under the Distribution Agreement.”
BRAINSTORM CELL THERAPEUTICS INC. reported the year ended December 31, 2023 results: net income $17.2 million, EPS $0.40.
“On April 1, 2024, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2023.”
BRAINSTORM CELL THERAPEUTICS INC. shareholders approved Ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2023-12-18 meeting.
“The proposal to ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2024 was approved, based upon the following votes:”
BRAINSTORM CELL THERAPEUTICS INC. shareholders approved Election of six nominees to the Board of Directors at the 2023-12-18 meeting.
“The six nominees (listed below) for election to the Company’s Board of Directors (the “Board”) were elected to hold office until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal, based upon the following votes:”
BRAINSTORM CELL THERAPEUTICS INC. reported the quarter ended September 30, 2023 results: net income Net loss for the three months ended September 30, 2023 was approximately $1.2 million, EPS Net loss per share for the three months ended September 30, 2023 and 2022 was $0.03 and $0.19, respectively.
“BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
“November 6, 2023, Brainstorm Cell Therapeutics Inc. (the “Company”) received a letter (the “MVLS Deficiency Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that from September 25, 2023 to November 3, 2023, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The MVLS Deficiency Notice has no immediate effect on the listing of the Company’s comm”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H), 5810(c)(3)(A)(ii)).
“November 1, 2023, Brainstorm Cell Therapeutics Inc. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on th”
BRAINSTORM CELL THERAPEUTICS INC. announced a restructuring with charges of approximately $450,000-$900,000 (approximately 30%).
“In connection with the RIF, the Company currently estimates it will incur a range of costs and expenses of approximately $450,000-$900,000, consisting primarily of cash severance costs and one-time termination benefits.”
Dr. Kirk Taylor departed as EVP and Chief Medical Officer at BRAINSTORM CELL THERAPEUTICS INC..
“Dr. Kirk Taylor, EVP and Chief Medical Officer, stepped down from his post, effective as of October 18, 2023.”
BRAINSTORM CELL THERAPEUTICS INC. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was approximately $5.3 million, EPS Net loss per share for the three months ended June 30, 2023 and 2022 was $0.13.
“BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.”
BRAINSTORM CELL THERAPEUTICS INC. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-07-17).
“the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”) , pursuant to which Maxim agreed to serve as exclusive placement agent for the issuance and sale of the shares of Common Stock and accompanying Common Warrants.”
BRAINSTORM CELL THERAPEUTICS INC. entered into Purchase Agreement valued at approximately $7.5 million (effective 2023-07-17).
“On July 17, 2023, Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to sell, in a public offering (the “Offering”), an aggregate of 4,054,055 shares of the Company’s common stock, par value $0.00005 per share (the “Common Stock”), together with accompanying warrants (the “Common Warrants”) to purchase 4,054,055 shares of Common Stock, at a purchase price of $1.85 per share and accompanying warrants for gross proceeds to the Company of approximately $7.5 million, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company.”
Nir Naor was elected as Director, Chair of Audit Committee at BRAINSTORM CELL THERAPEUTICS INC..
“On June 19, 2023, the Board elected Nir Naor to serve as a member of the Board, effective June 20, 2023, filling the vacancy created by Mr. Taub’s resignation.”
Malcolm Taub resigned as Director at BRAINSTORM CELL THERAPEUTICS INC..
“On June 15, 2023, Malcolm Taub notified the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) of his decision to resign from the Company’s Board, and all committees thereof, effective as of the close of business on June 15, 2023.”
David Setboun resigned as Chief Operating Officer at BRAINSTORM CELL THERAPEUTICS INC..
“On May 18, 2023, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer of Brainstorm Cell Therapeutics Inc. (the “Company”), notified the Company of his decision to resign from his role effective as of May 31, 2023 to pursue another opportunity.”
BRAINSTORM CELL THERAPEUTICS INC. reported the quarter ended March 31, 2023 results: net income Net loss ... was approximately $5.1 million, EPS Net loss per share ... was $0.14.
“Net loss for the three months ended March 31, 2023 was approximately $5.1 million, as compared to a net loss of approximately $5.4 million for the three months ended March 31, 2022. Net loss per share for the three months ended March 31, 2023 and 2022 was $0.14 and $0.15, respectively.”
BRAINSTORM CELL THERAPEUTICS INC. reported the fiscal year ended December 31, 2022 results: net income approximately $30.3 million.
“Net loss for the twelve months ended December 31, 2022, was approximately $”
BRAINSTORM CELL THERAPEUTICS INC. shareholders approved Ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the current fiscal year at the 2023-01-10 meeting.
“The proposal to ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s current fiscal year was approved, based upon the following votes: Votes For Votes Withheld Votes Against Abstentions Broker Non-Votes 23,320,844 N/A 482,449 66,099 N/A”
BRAINSTORM CELL THERAPEUTICS INC. shareholders approved Election of seven nominees to the Board of Directors at the 2023-01-10 meeting.
“1. The seven nominees (listed below) for election to the Company’s Board of Directors (the “Board”) were elected to hold office until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal, based upon the following votes: Votes For Votes Withheld Votes Against Abstentions Broker Non-Votes Dr. Irit Arbel 10,568,981 226,705 N/A N/A 13,073,706 Dr. June S. Almenoff 10,481,733 313,953 N/A N/A 13,073,706 Dr. Anthony Polverino 10,621,912 173,774 N/A N/A 13,073,706 Dr. Jacob Frenkel 10,637,258 158,428 N/A N/A 13,073,706 Malcolm Taub 10,516,216 279,470 N/A N/A 13,073,706 Uri Yablonka 10,597,289 198,397 N/A N/A 13,073,706 Dr. Menghisteab Bairu 10,652,336 143,350 N/A N/A 13,073,706”
Dr. Ralph Kern departed as President and Chief Medical Officer at BRAINSTORM CELL THERAPEUTICS INC..
“Effective as of January 3, 2023, the Kern Separation Amendment terminates the employment agreement previously entered into between the Company and Dr. Kern on February 28, 2017.”
Dr. Stacy Lindborg was appointed as Co-Chief Executive Officer at BRAINSTORM CELL THERAPEUTICS INC..
“Dr. Lindborg will be appointed to the position of Co-Chief Executive Officer of the Company.”
BRAINSTORM CELL THERAPEUTICS INC. reported the third quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022, was approximately $6.9 million, EPS Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19.
“Net loss for the three months ended September 30, 2022, was approximately $6.9 million, as compared to a net loss of approximately $5.3 million for the three months ended September 30, 2021. Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19 and $0.15, respectively.”
BRAINSTORM CELL THERAPEUTICS INC. reported first quarter ended March 31, 2022 results: net income approximately $5.4 million, EPS $0.15.
“Net loss for the three months ended March 31, 2022, was approximately $5.4 million, as compared to a net loss of approximately $6.7 million for the three months ended March 31, 2021. Net loss per share for the three months ended March 31, 2022, and 2021 was $0.15 and $0.19 respectively.”
Sankesh Abbhi retired as Director at BRAINSTORM CELL THERAPEUTICS INC..
“On December 14, 2021, Sankesh Abbhi retired from the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”), effective immediately prior to the commencement of the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company.”
Sankesh Abbhi departed as Director at BRAINSTORM CELL THERAPEUTICS INC..
“On October 27, 2021, Sankesh Abbhi informed the Board of his intention not to stand for re-election at the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”), and to retire from the Board effective immediately prior to the commencement of the Annual Meeting.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.